|
|
|
Insider
Information: |
Vessey Rupert |
Relationship: |
EVP & President, Resea... |
City: |
Summit |
State: |
NJ |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
55,636 |
|
Indirect Shares
|
656 |
|
|
Direct
Value |
$2,599,961 |
|
|
Indirect Value
|
$27,388 |
|
|
Total
Shares |
56,292 |
|
|
Total
Value |
$2,627,349 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
9
|
Stock
price went up :
|
0
|
6
|
Stock
price went down : |
0
|
3
|
|
|
|
Gain/Loss Ratio : |
0.0
|
2.0
|
Percentage
Gain/Loss : |
0.0%
|
9.3%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
Techne Corp |
TECH |
Director |
2023-10-26 |
7,885 |
2019-07-01 |
0 |
Premium* |
|
Bristol-Myers Squibb Co |
BMY |
EVP & President, Resea... |
2023-05-03 |
47,751 |
2023-05-03 |
656 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
79 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 4
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
|
2019-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
613 |
613 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
|
2019-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
14,178 |
14,178 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
|
2019-12-31 |
4 |
D |
$64.19 |
$507,743 |
D/D |
(7,910) |
22,868 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
|
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,060 |
30,778 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
|
2020-02-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,592 |
25,920 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
|
2020-02-04 |
4 |
D |
$64.29 |
$74,769 |
D/D |
(1,163) |
24,757 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
|
2020-03-01 |
4 |
D |
$59.06 |
$526,992 |
D/D |
(8,923) |
39,183 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
|
2020-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,349 |
48,106 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
|
2020-03-02 |
4 |
S |
$60.59 |
$5,108,222 |
D/D |
(84,308) |
48,343 |
0 |
% |
|
BMY |
Bristol-Myers Squibb Co |
Pres., Research & Early Dev. |
|
2020-03-02 |
4 |
OE |
$38.41 |
$4,831,452 |
D/D |
93,468 |
132,651 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2020-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,707 |
59,050 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2020-05-01 |
4 |
D |
$60.26 |
$317,811 |
D/D |
(5,274) |
53,776 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2020-10-30 |
4 |
D |
$58.45 |
$167,109 |
D/D |
(2,859) |
56,721 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2020-10-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,804 |
59,580 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2020-11-19 |
4 |
OE |
$38.41 |
$2,572,887 |
D/D |
52,213 |
98,355 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2020-11-19 |
4 |
S |
$61.25 |
$3,530,269 |
D/D |
(57,591) |
51,343 |
0 |
% |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2020-11-23 |
4 |
S |
$61.34 |
$823,244 |
D/D |
(13,421) |
37,922 |
0 |
% |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2020-12-02 |
4 |
D |
$62.18 |
$280,183 |
D/D |
(4,506) |
42,208 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2020-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,792 |
46,714 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2020-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,866 |
68,074 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2020-12-31 |
4 |
D |
$62.03 |
$822,332 |
D/D |
(13,257) |
54,817 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2021-02-04 |
4 |
D |
$61.56 |
$73,010 |
D/D |
(1,186) |
57,223 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2021-02-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,592 |
58,409 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2021-03-01 |
4 |
D |
$61.63 |
$551,219 |
D/D |
(8,944) |
71,628 |
0 |
- |
|
BMY |
Bristol-Myers Squibb Co |
EVP, Research & Early Dev. |
|
2021-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,349 |
80,572 |
0 |
- |
|
79 Records found
|
|
Page 1 of 4 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|